Nicox S.A. (LON:0RCQ)
London flag London · Delayed Price · Currency is GBP · Price in EUR
0.3750
+0.0140 (3.88%)
At close: Jul 29, 2025

Nicox Company Description

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally.

The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.

It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation.

In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis.

Nicox S.A. was founded in 1996 and is headquartered in Biot, France.

Nicox S.A.
CountryFrance
Founded1996
IndustryPharmaceutical Preparations
Employees28
CEOGavin Spencer

Contact Details

Address:
Sundesk Sophia Antipolis
Biot, 06410
France
Phone33 4 97 24 53 00
Websitenicox.com

Stock Details

Ticker Symbol0RCQ
ExchangeLondon Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyEUR
SIC Code2834

Key Executives

NamePosition
Andreas Rutger Segerros M.B.A., M.Sc.Chief Executive Officer
Dr. Michele Garufi Ph.D.Co-Founder and Interim Chairman
Sandrine GestinVice President of Finance
Doug HubatschChief Scientific Officer
Emmanuelle PierryGeneral Counsel and Head of Legal Affairs
Dr. Gavin M. SpencerExecutive Vice President, Chief Business Officer and Head of Corporate Development
Dr. Ramesh KrishnamoorthySenior Director and Head of Late Stage CMC and Quality Control
Dr. Jose BoyerConsultant
Dr. Ennio Ongini Ph.D.Consultant